Srs Capital Advisors, Inc. Atea Pharmaceuticals, Inc. Transaction History
Srs Capital Advisors, Inc.
- $8.6 Billion
- Q3 2025
A detailed history of Srs Capital Advisors, Inc. transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 199 shares of AVIR stock, worth $589. This represents 0.0% of its overall portfolio holdings.
Number of Shares
199Holding current value
$589% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AVIR
# of Institutions
123Shares Held
49.3MCall Options Held
54KPut Options Held
98K-
Black Rock Inc. New York, NY9.12MShares$27 Million0.0% of portfolio
-
Bml Capital Management, LLC Zionsville, IN7.47MShares$22.1 Million19.85% of portfolio
-
Tang Capital Management LLC San Diego, CA4.83MShares$14.3 Million0.64% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.71MShares$13.9 Million0.0% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA2.49MShares$7.36 Million2.31% of portfolio
About Atea Pharmaceuticals, Inc.
- Ticker AVIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,258,600
- Market Cap $246M
- Description
- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...